Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The ERBB network facilitates KRAS-driven lung tumorigenesis.

Science translational medicine - 20 Jun 2018

Kruspig Björn, Monteverde Tiziana, Neidler Sarah, Hock Andreas, Kerr Emma, Nixon Colin, Clark William, Hedley Ann, Laing Sarah, Coffelt Seth B, Le Quesne John, Dick Craig, Vousden Karen H, Martins Carla P, Murphy Daniel J

Abstract excerpt

KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling; however, recent data suggest that this independence may not be absolute. We show that initiation and progression of KRAS-driven lung tumors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Extracellular Signal-Regulated MAP Kinases

Share to Gene Regulatory Networks

Share to Mitogen-Activated Protein Kinase Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 29925636
DOI: 10.1126/scitranslmed.aao2565
PMCID: PMC6881183

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The ERBB network facilitates KRAS-driven lung tumorigenesis.PMID 29925636Read ↗

The ERBB network facilitates KRAS-driven lung tumorigenesisSemantic proximity Read ↗

BRAF <sup>V600E</sup> -Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor SignalingSemantic proximity Read ↗

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.Semantic proximity Read ↗

The genetics and biology of KRAS in lung cancer.Semantic proximity Read ↗

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.Semantic proximity Read ↗

Targeting KRAS mutant lung cancer: light at the end of the tunnel.Semantic proximity Read ↗

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.Semantic proximity Read ↗

ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinomaSemantic proximity Read ↗

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.Semantic proximity Read ↗

The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1Semantic proximity Read ↗

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.